There is no announced date. Retatrutide is an investigational drug that the FDA has not approved for any use, and it is not available from any pharmacy or compounding facility.
Retatrutide is in Phase 3 clinical trials conducted by Eli Lilly. Eli Lilly has not announced a target date for submitting a New Drug Application, and the FDA has not approved retatrutide for any indication.
Any date you see quoted for retatrutide's availability — on a forum, a vendor site, or a news roundup — is speculation. A drug becomes available only after trials are completed, a sponsor submits an application, and the FDA independently reviews the data and reaches a decision. None of those steps has happened here, and none is guaranteed to happen: investigational drugs are discontinued at every phase of development, including Phase 3.
We deliberately do not publish a predicted approval year. A prediction would imply a confidence about this drug's future that nobody outside that review process is in a position to have.
The steps between where retatrutide stands now and any possible availability are: completion of the Phase 3 trials and analysis of their data; submission of a New Drug Application by the sponsor; and an FDA review of that application, which is a substantive scientific evaluation rather than a formality.
At the end of that review the FDA may approve the application, may require additional studies, or may decline it. Timelines move when enrollment runs slow, when safety questions arise, or when regulators ask for more data.
Being in Phase 3 is a statement about where testing currently stands. It is not a signal that approval is near, or that it is likely.
A compounding pharmacy may only compound preparations from active ingredients permitted under the compounding statutes, which requires FDA approval of the ingredient. Retatrutide is not approved, so no 503A or 503B facility may lawfully compound it. There is no such thing as a legitimate compounded retatrutide product.
Sellers offering "research grade" retatrutide, or offering it for personal use, are outside the lawful supply chain. Those products are not tested for identity, purity, potency, or sterility by any regulator, and a buyer has no way to verify what is in the vial.
If you are looking for medical weight management now, the productive step is a conversation with a licensed provider about options that have completed FDA review and are lawfully available, and whether any of them is appropriate for you. That is a clinical judgment that depends on your health history, not something to settle from an article.
Waiting for an investigational drug is not a treatment plan. There is no assurance that retatrutide will be approved, and no assurance about when.